Affordable Access

Publisher Website

Upregulation of formyl-peptide and interleukin-8—induced eosinophil chemotaxis in patients with allergic asthma

Authors
Journal
Journal of Allergy and Clinical Immunology
0091-6749
Publisher
Elsevier
Publication Date
Volume
91
Issue
6
Identifiers
DOI: 10.1016/0091-6749(93)90323-8
Keywords
  • Allergens
  • Ige
  • Mediators
  • Inflammatory Mechanisms

Abstract

Abstract Background: The cytokine granulocyte-macrophage colony-stimulating factors, interleukin-3 and interleukin-5, are important modulators of eosinophilia and eosinophil function. In particular, eosinophil chemotaxis is very sensitive to cytokine priming. Methods: We evaluated chemotactic responses of eosinophils from patients with allergic asthma. These cells exhibited a primed phenotype as deduced from enhanced responses toward formyl-methionyl-leucyl-phenylalanine and platelet-activating factor and a decreased responsiveness toward granulocyte-macrophage colony-stimulating factor. Bronchoprovocation of patients with allergic asthma with allergen was performed as a possible means to enhance in vivo priming. Results: Indeed, eosinophils isolated 3 hours after allergen challenge exhibited a more pronounced primed phenotype, which was reflected by an induction of responsiveness towards interleukin-8. Eosinophil responses induced by platelet-activating factor, formyl-methionyl-leucyl-phenylalanine, complement fragment C5a, interleukin-3, interleukin-5, and granulocyte-macrophage colony-stimulating factor were not significantly altered after allergen challenge. Conclusion: These data provide further evidence that eosinophils are already primed in the peripheral blood of individuals with allergic asthma. This is most likely due to the presence of circulating cytokines in the peripheral blood of those individuals. This in vivo priming results in selective upregulation and downregulation of responses toward various chemotaxins, which may be released in the lungs during allergic inflammation.

There are no comments yet on this publication. Be the first to share your thoughts.